Combination of APS, HMGN1, and anti-TNFR2 antibody remodels the tumor immune microenvironment to enhance antitumor immunity in colorectal cancer Authors: Liming Zhao, Xia Pei, Haobo Wu, Shengwen Zhou, Jia Song, Quan Wan, Hang Lv, Jing Xu, Yingjie Nie Published: 2026 ABSTRACT Highlights•Astragalus polysaccharide synergizes with HMGN1 and anti-TNFR2 antibody in a colorectal cancer model.•Combination therapy markedly suppresses tumor growth in murine colorectal cancer.•Enhances CD8+T cell activation and reduces treg-mediated immunosuppression.•Induces durable and tumor-specific immune memory responses.•Provides a promising immunotherapeutic strategy for CRC treatment.Keywords: Astragalus polysaccharide, HMGN1, Anti-TNFR2 antibody, Immunotherapy, Tumor microenvironment Introduction Colorectal cancer (CRC) is one of the three most prevalent cancers worldwide and the second leading cause of cancer-related death worldwide [1,2]. Although surgery, radiotherapy, and cytotoxic agents remain the main treatment options, their efficacy is insufficient for advanced, recurrent, and metastatic CRC [3]. Conventional chemotherapy has long been a cornerstone of systemic antitumor therapy, but its clinical benefit is limited by major drawbacks, including nonspecific cytotoxicity, dose-limiting toxicity, and the emergence of drug resistance, all of which compromise durable therapeutic responses [4,5]. Recently, the development of immunotherapy has opened new perspectives for CRC treatment [6]. However, the intrinsically immunosuppressive tumor microenvironment of CRC strongly limits therapeutic responsiveness, often leading to therapy failure and tumor recurrence [7]. Therefore, it is critical to develop novel strategies that can remodel the tumor microenvironment (TME) and induce a persistent antitumor immune response. The TME is a complex network of interactions among various immune cell types, structural elements, and signaling molecules involved in oncogenesis, progression, and immune evasion [8]. Strategies aimed at modulating the TME are currently considered effective approaches for combating tumor immune evasion [9]. The common principle underlying these strategies is their aim to reactivate antitumor immunity by restoring a balanced interaction between antigen-presenting cells (APCs) such as dendritic cells(DCs), cytotoxic T cells, and immunosuppressive T cell subsets, thereby re-establishing an appropriate immune response to tumors [[10], [11], [12]]. However, the continued presence of immunosuppressive components in the TME including hyperaccumulation of regulatory T cells (Tregs) and defective cytotoxic T-cell function, remains a major challenge for immunotherapy. Polysaccharides derived from natural sources with immunomodulatory and anticancer properties have been extensively investigated in recent years [13,14]. Among them, Astragalus polysaccharide (APS), isolated from Astragalus membranaceus, exhibits various pharmacological activities, including modulation of immune function, inhibition of tumor progression, and free-radical scavenging [[15], [16], [17], [18]]. Importantly, APS has been shown to modulate the TME and enhance immune surveillance, supporting its potential use in combination with cancer therapy [[19], [20], [21]]. HMGN1 is a highly mobile nucleoprotein and a natural agonist of Toll-like receptor 4 (TLR4), promoting DC maturation and inducing Th1 responses [[22], [23], [24], [25]]. In addition, TNFR2 with selective expression in Tregs is a novel target for immunomodulation since blocking antibodies against TNFR2 can overcome Treg mediated inhibition and rescue effector T cell function. Recent studies have shown limited clinical success in CRC when targeting HMGN1 and/or utilizing anti-TNFR2 therapy, either individually or in combination [26,27], highlighting the limitations of single-target approaches and the need to identify agents capable of acting on multiple targets. Taken together, these findings suggest that the combination of APS, HMGN1, and an anti-TNFR2 antibody may exert multiple immunomodulatory effects, thereby enhancing antitumor efficacy. In this study, we established a CT26 murine CRC model to evaluate the therapeutic efficacy of APS in combination with HMGN1 and an anti-TNFR2 antibody. We further investigated the effects of this combination therapy on antitumor immunity, with particular emphasis on its ability to inhibit Tregs and activate CD8+ T cells. Methods and materials Mice and cell culture Female BALB/c mice aged eight weeks were purchased from Guangdong Zhiyuan Biomedical Technology Co, Ltd. and kept under sterile conditions, with free access to food and water. All animal experiments were approved by the Animal Ethics Committee of Shenzhen Huarui Model Biotechnology (No. APS-250103-026-01). Cell Lines: murine CT26, MC38, and 4T1 cells were purchased from Pricella (Wuhan, China), and the human HCT116 cells were bought from Servicebio (Wuhan, SW480, SW620 cell lines: kindly provided by Professor Fengming Kong (The University of Hong Kong Shenzhen Hospital). Cell culture conditions varied among the different cell lines. CT26, 4T1, SW480 and SW620 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, MC38 and HCT116 cells were maintained in DMEM containing 10% FBS, penicillin (100 U/mL), streptomycin (100 µg/mL), and glutamine (2 mM). All cells were incubated at 37°C in a humidified incubator with 5% CO₂. Generation of bone marrow-derived dendritic cells BMDCs: Bone marrow cells were isolated from BALB/c mice femurs, erythrocytes were lysed out, and then cultured with RPMI-1640 containing 20 ng/mL IL-4 and 10 ng/ml GM-CSF for 6 days to generate BMDCs. After these differentiation steps, the cell populations were treated with different stimulators like APS or bacterial LPS, HNGN, anti-TNFR2 antibody or HMGN1 along with anti-TNFR2 antibody for periods of time between 24 and 48 hours. The resulting DCs were characterised and the experimental sample was prepared as follows. Chemicals All chemicals used were of analytical grade. Ammonium persulfate (APS, Cat. No. A7970) was obtained from Solarbio (Beijing, China). High mobility group nucleosome-binding protein 1 (HMGN1) was purchased from Bio-Techne (R&D Systems, USA), and anti-mouse TNFR2 (CD120b, clone TR75-54.7) from BioXCell (West Lebanon, NH, USA). Cell Counting Kit-8 (CCK-8) was sourced from MedChem Express (Monmouth Junction, NJ, USA). ELISA kits for interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β) were obtained from Servicebio (Wuhan, China). Fetal bovine serum (FBS) was supplied by Pricella (Wuhan, China), and penicillin–streptomycin solution from New Cell & Molecular Biotech (Suzhou, China). Trypsin-EDTA (0.25%), trypsin, and phenol red (0.25%) were purchased from Servicebio (Wuhan, China). RPMI-1640 medium was acquired from GIBCO BRL (Grand Island, NY, USA). For flow cytometry, the following antibodies were obtained from BD Biosciences (Franklin Lakes, NJ, USA): FITC-anti-mouse CD4 (clone GK1.5), BV510-anti-mouse CD45 (clone 30-F11), APC-anti-mouse CD3 (clone 145-2C11), PerCP-Cy5-anti-mouse CD8 (clone 53-6.7), PE-Cy7-anti-mouse CD25 (clone PC61), BV421-anti-mouse FoxP3 (clone MF23), BV605-anti-mouse TIM-3 (CD366, clone 5D12/TIM-3), Fixable Viability Stain 700, FITC-anti-mouse CD45 (clone 30-F11), BV421-anti-mouse CD11c (clone N418), PE-anti-mouse I-A/I-E (MHCII, clone M5/114), PE-Cy7-anti-mouse CD86 (clone GL1), and APC-anti-mouse CD80 (clone 16-10A1). Cell viability assay Cells were plated in 96-well plates at a density of 3 × 10³ cells per well and exposed to APS or anti-TNFR2 antibody for 24–96 hours. Cell viability was assessed using the CCK-8 assay following the manufacturer’s instructions, with three biological replicates for each condition. Absorbance was measured at 450 nm using a microplate reader. Experimental tumor model and therapeutic regimen CT26 colon carcinoma and/or 4T1 mammary carcinoma cells were injected subcutaneously (2 × 105cells in 100 µL PBS, n=1/mouse) to BALB/c mice on the right flanks. The tumor volumes were measured every 3 days as follows: with volumes calculated according to the following formula: (length of tumor × width²)/2. The termination criteria was set to a tumor size of 1500 mm3 and the mice were sacrificed for humane reasons. Treatment started after the tumors reached a diameter of approximately 100 mm3 (usually on day 12 after cell injection), followed by daily IP administration of APS (200 mg/kg) over a period of 14 days.anti-TNFR2 antibody(200 μg in 100 μL) by intraperitoneal administration on day 13, 16, 19, and 22. HMGN1 (1μg in 100 μL) was injected intratumorally on days 14, 17, 20, and 23. For the rechallenge experiments, the tumor-free animals were rechallenged with 2 × 105 CT26 or 2 × 105 4T1cells into their right abdomen or left flanks respectively after 60 days from the start date. On the next day, tumor tissues and related lymph nodes were obtained. Flow cytometry analysis Tumors, spleens, and lymph nodes were dissociated to single-cell suspensions for flow cytometric analysis. To profile the CD8+ T cells as well as exhausted subpopulations of CD8+ T cells, fluorescently labeled as follows: CD45-BV510 CD45 (Clone 30-F11, Cat. No. 563891, BD Biosciences, USA), CD3-APC (Clone 145-2C11, Cat. No. 553066, BD Biosciences, USA), CD8-PE-Cy5.5 (Clone 53-6.7, Cat. No. 551162, BD Biosciences, USA), Tim3-BV605 (Clone 5D12, Cat. No. 747624, BD Biosciences, USA); the number of CD4+T cells and Treg were determined by fluorescent labels of CD45-BV510, FITC-CD4(Clone GK1.5, Cat. No. 557307, BD Biosciences, USA), PE-Cy7-CD25 (Clone PC61, Cat. No. 552880, BD Biosciences, USA), BV421-Foxp3 (Clone MF23, Cat. No. 562996, BD Biosciences, USA) and APC-CD3 (Clone 145-2C11, Cat. No. 553066, BD Biosciences, USA) markers. DC: BV510-CD45(Clone 30-F11, Cat. No. 563891, BD Biosciences, USA), BV421-CD11c (Clone N418, Cat. No. 565452, BD Biosciences, USA), PE-MHCII (Clone M5/114, Cat. No. 562010, BD Biosciences, USA), APC-CD80 (Clone 16-10A1, Cat. No. 560016, BD Biosciences, USA), PE-Cy7-CD86 (Clone GL1, Cat. No. 560582, BD Biosciences, USA) were analyzed using the following fluorochrome-conjugated monoclonal antibodies; all antibodies mentioned hereinafter will be labeled with its corresponding fluorescence tag. Fluorescence channels used for antibody labeling was based on the flow cytometer capabilities; for example, APC labelled antibody was measured in the AF647 channel and PE-Cy5.5 labelled antibody in the PE-Cy5 channel. Data was acquired on the BD Fortessa flow cytometer and analyzed using FlowJo10 software. Serum cytokine analysis Serum levels of certain cytokines (IL-2(Cat. No. GEM0038), IL-6(Cat. No. GEM0001), IL-10(Cat. No. GEM0003), TNF-α (Cat. No. GEM0004), TGF-β (Cat. No. GEM0051) were detected by ELISA kits (Servicebio, Wuhan, China) according to the instructions from the manufacturer. Statistical analysis In vitro experimental data are presented as mean ± standard deviation (SD), while in vivo experimental data are reported as mean ± standard error of the mean (SEM). Two treatment groups were compared using an independent t-test, and comparisons among three or more groups were made using one-way or two-way analysis of variance (ANOVA). Survival data were analyzed using the Log-rank test. Post hoc multiple comparisons were conducted using Tukey's test as required by the analysis. All statistical analyses were performed using GraphPad Prism 9 software, with p < 0.05 considered statistically significant. Results Anti-proliferative effects of APS and anti-TNFR2 antibody alone and in combination in colorectal cancer cell lines To evaluate the anti-proliferative effects of APS, anti-TNFR2 antibody, and their combination in CRC, five CRC cell lines (CT26, MC38, SW480, SW620, HCT116) were treated with gradient concentrations of each agent, either alone or in combination, for 24 to 96 hours. Cell viability was assessed after treatment. Both single agents exhibited anti-proliferative effects in a time- and dose-dependent manner, with notable inter-cell line variability. For APS, concentrations below 1000 μg/mL had minimal impact on cell viability after 24 hours. However, prolonged exposure (96 hours) to 200 μg/mL significantly reduced cell viability in all cell lines. At doses ≥1500 μg/mL, significant growth inhibition was observed within 48 hours in most cell lines, with MC38 requiring 2000 μg/mL for detectable suppression. Among the human cell lines, SW620 showed the highest sensitivity to APS, with significant inhibition observed at 2000 μg/mL after 24 hours (Fig. 1A-E) Anti-proliferative effects of APS and anti-TNFR2 antibody alone and in combination in colorectal cancer cell lines. (A-E) Different CRC cells (CT26, MC38, SW480, SW620, and HCT116 cells) were treated with various concentrations of APS (0-2000 μg/mL) for 24h, 48h, 72h, or 96h, and cell viability was assessed using CCK-8 assay. (F-K) CRC cells were treated with the indicated concentrations (0-50 µg/mL) of anti-TNFR2 antibody (T) for 24h, 48h, 72h, or 96h, and cell viability was assessed by CCK-8 assay. (M, N) CT26 cells were treated with various concentrations of APS and 10 µg/mL of T for 24h or 48h, cell viability was measured using CCK-8 reagent. (Statistical analysis: For panels (A-K), statistical significance was determined using two-way ANOVA to evaluate the effects of APS concentration and incubation time; for panels (M-N), statistical significance was determined using one-way ANOVA. Data are expressed as means ± SD from triplicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05.). Anti-TNFR2 monotherapy induced significant growth inhibition in all cell lines at concentrations exceeding 40 μg/mL after 48 hours. After 24 hours, 50 μg/mL of anti-TNFR2 significantly inhibited proliferation in all cell lines except CT26 and HCT116. SW620 cells showed the highest sensitivity, with significant inhibition observed after 48 hours at approximately 10 μg/mL. In contrast, SW480 cells were less sensitive, requiring at least 40 μg/mL to achieve inhibition comparable to that in HCT116 cells (Fig. 1F-K). In addition, CT26 cells were treated with varying concentrations of APS in combination with a low dose of anti-TNFR2 antibody (10 µg/mL). The combination of 100 μg/mL APS and anti-TNFR2 antibody induced significant growth inhibition after 48 hours, while neither monotherapy showed detectable anti-proliferative activity at the same time point. (Fig. 1M, 1N). Combined APS and HMGN1 treatment enhances DC maturation To evaluate the immunomodulatory effects of APS and HMGN1 on DC, we treated bone marrow-derived dendritic cells (BMDCs) with APS or HMGN1 alone or in combination, and assessed cell maturation based on CD80 and CD86 expression on the cell surface. Lipopolysaccharide (LPS) was used as a positive control. High concentrations (>200 µg/mL) and prolonged incubation (48 hours) of APS were required for significant maturation. In contrast, HMGN1 was effective at much lower concentrations (0.3-0.5 μg/mL) after just 24 hours. The administration of anti-TNFR2 antibody did not significantly affect DC maturation at either 24 or 48 hours (Fig. 2A–F). Combined APS and HMGN1 Treatment Enhances DC Maturation. (A) Proportion of CD80+CD86+ DCs after 24 h of treatment with different concentrations of APS (0, 50, 100, 200, 400 μg/mL) and LPS (100 ng/mL). (B) Proportion of CD80+CD86+ DCs after 48 h of treatment with different concentrations of APS (0, 50, 100, 200, 400 μg/mL) and LPS (100 ng/mL). (C) Proportion of CD80+CD86+ DCs after 24 h of treatment with different concentrations of HMGN1(N1) (0.1, 0.3, 0.5 μg/mL). (D) Proportion of CD80+CD86+ DCs after 24 h of treatment with different concentrations of anti-TNFR2 antibody (T) (5, 10, 20 μg/mL). (E) Proportion of CD80+CD86+ DCs after 48 h of treatment with different concentrations of N1 (0.1, 0.3, 0.5 μg/mL). (F) Proportion of CD80+CD86+ DCs after 48 h of treatment with different concentrations of T (5, 10, 20 μg/mL). (G,H) The percentage of CD80⁺CD86⁺ DCs after treatment with 200 μg/mL APS for 24 or 48 h, in the presence of N1 or in combination with N1 and T.(I) Flow cytometry profile, and quantification for the population of CD80+, CD86+ DC at 24 h, and 48 h post-concomitant treatment with APS (200 μg/mL), N1 (0.5 μg/mL), and T (5 μg/mL) were added. (For panels (A-H), statistical significance was determined using one-way analysis of variance (ANOVA); For panel (I), statistical significance was determined using t-test. Data are presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05.). Notably, combined treatment with APS and HMGN1 significantly increased the levels of CD80+CD86+ DC compared to either monotherapy, with the best results obtained by combining 200 µg/mL APS and 0.5 µg/mL HMGN1 (Fig. 2G, H). Furthermore, anti-TNFR2 antibody treatment enhanced this effect, although no significant difference was observed between the 24 h and 48 h time points (Fig. 2I). Triple combination of APS, HMGN1, and anti-TNFR2 antibody suppresses tumor growth and prolongs survival in vivo To evaluate the efficacy of the triple combination therapy, this study was conducted in a CT26 tumor-bearing mouse model. As shown in the experimental design of Fig. 3A, the treatment groups were administered a combination of APS, HMGN1, and anti-TNFR2 antibody. Triple combination of APS, HMGN1, and anti-TNFR2 antibody suppresses tumor growth and prolongs survival in vivo. (A) Schematic diagram of the experimental design. When the tumor volume reached 100 mm³ (on day 12), mice were treated with PBS or APS (4 mg/200μg per mouse on days 13-26), anti-TNFR2 antibody (200 μg/100μL per mouse on days 13, 16, 19, and 22), and HMGN1 (1 μg/100μL per mouse on days 14, 17, 20, and 23). (B) Representative images of tumors on day 27. (C) Tumor growth curves for different treatment groups (n=10). Data are presented as mean ± SEM and were analyzed using two-way ANOVA to evaluate. (D) Tumor volume on day 27 (n=10). Results are expressed as mean ± SD and were analyzed using one-way ANOVA. (E) Body weight changes over time, monitored at 2-day intervals for each group (n=10). Data are presented as mean ± SEM and were analyzed using two-way ANOVA. (F) Representative images of spleens from each group on day 27 (n=5). (G) Liver weight to body weight ratio for each group (n=5). Results are expressed as mean ± SD and were analyzed using one-way ANOVA. (H)Survival curves for each group (n=10). Comparisons were made using the log-rank test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05.). The results showed that, compared to the untreated group, the triple combination therapy significantly inhibited tumor progression (Fig. 3B-D), with no significant changes observed in the mean body weight (Fig. 3E) or spleen index (Fig. 3F, 3G) of the mice.By day 60 post-treatment, 80% of the mice achieved complete tumor regression, which resulted in a significant prolongation of survival (Fig. 3H). Triple combination therapy reshapes immune cell composition and enhances CD8⁺ T cell responses To assess the effect of this combination therapy on immunity, we evaluated immune cells by flow cytometry from a variety of tissues,including malignant tissue, spleen, tumor draining lymph nodes (TDLNs), and non tumor draining lymph nodes (NTDLNs) using standard gates.APS + HMGN1 + Anti-TNFR2 antibody treatment significantly reduced the proportion of CD4+ T cells in tumour tissues, but not significantly altered frequencies of CD4+ T cells within the TDLNs (Fig. 4A-E). Triple combination therapy reshapes immune cell composition and enhances CD8⁺ T cell responses. (A-E) The proportion of CD4⁺ T cells among CD3⁺ cells in the tumor, spleen, TDLNs, and NTDLNs. (n=5). (F-J) The proportion of CD8⁺ T cells among CD3⁺ cells in the tumor, spleen, TDLNs, and NTDLNs (n=5). (All data are presented as mean ± SD and were analyzed using one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05). On the other hand, we observed that treatment induced an overall increase of CD8+ cells at all locations, including tumors, spleens, TDLNs, and NTDLNs (Fig. 4F-J). Triple combination therapy alleviates colorectal cancer immunosuppression by targeting immune cells and cytokine networks To assess the immunosuppression-modulating effect of the triple therapy, we quantified the frequencies of CD4⁺CD25⁺Foxp3⁺ Tregs and TIM-3⁺ exhausted CD8⁺ T cells in tumor tissues, spleens, and draining lymph nodes (DLNs) using flow cytometry. Notably, compared with the control group, triple therapy treatment significantly reduced Treg frequencies across all three examined tissues, with a distinct tissue-specific gradient of Treg downregulation: the most pronounced reduction was observed in the spleen, followed by DLNs, and the smallest decrease was detected in the tumor (Fig. 5A-E). Meanwhile, TIM-3⁺ exhausted CD8⁺ T cell proportions were significantly lower in all three tissues of the triple therapy group relative to controls (Fig. 5F-J), indicating effective reversal of CD8⁺ T cell dysfunction by the treatment. Triple combination therapy alleviates colorectal cancer immunosuppression by targeting immune cells and cytokine networks. (A-E) The ratio of CD4+CD25+Foxp3+ Tregs among CD4+ cells in the tumor, spleen, TDLNs, and NTDLNs (n=5). (F-J) Percentage of Tim3+ cells among CD8+ T cells in the tumor, spleen, TDLNs, and NTDLNs(n=5). (K-O) Serum circulating cytokines were quantified from the serum samples, including IL-2, IL-10, TNF-α, TGF-β, IL-6 with 5 samples each in an experimental group. (All data are presented as mean ± SD and were analyzed using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05.). To further support this finding, we performed circulating cytokine profiling to validate the shift in immune functional status. Serum levels of the effector-polarizing cytokines IL-2 and TNF-α were significantly elevated in the triple therapy group (Fig. 5K, 5M), whereas the levels of immunosuppressive cytokines IL-10 and TGF-β, as well as the pro-tumorigenic inflammatory cytokine IL-6, were markedly downregulated (Fig. 5L, 5N, 5O). Triple combination therapy induces durable tumor-specific immune memory and inhibits 4T1 breast cancer tumor growth To determine whether the triple combination confers long-term protective immunity, cured CT26-bearing mice were rechallenged 60 days after tumor clearance. No tumor growth was observed upon re-challenging with CT26 cells on the treated side, whereas 4T1 cells implanted simultaneously on the contralateral side readily formed tumors (Fig. 6A, 6B), demonstrating tumor-specific immune memory. Triple Combination Therapy Induces Durable Tumor-Specific Immune Memory and Inhibits 4T1 Breast Cancer Tumor Growth. (A, C) Schematic diagrams of re-challenging the tumor-free mice. (B) Tumor growth curves of the tumor-free (T-free) and naive groups (n = 3). (D) Photographs of harvested tumors at day 27. (E) Tumor growth curves (n=5). Data are represented as mean ± SEM and were analyzed using two-factor ANOVA. (F)Tumor volume on day 27(n=5). Results are expressed independent t-test as mean ± SD and were analyzed using independent t-test. (G) Body weight of mice on day 27. Results are expressed as mean ± SD and were analyzed using independent t-test. (H) Body weight change over time (n=5). (I) Survival curves of the mice(n=5). Comparisons were made using the log-rank test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = no significant difference, P > 0.05.). To further assess systemic protection, 4T1 cells were implanted on the treated side, while CT26 cells were injected on the contralateral side. Remarkably, neither tumor established growth, indicating that the therapy not only induces CT26-specific immune memory but also enhances broader antitumor immunity (Fig. 6C). We next established a 4T1 tumor–bearing mouse model using the same regimen as in CT26 studies. Combination therapy markedly reduced tumor growth compared to controls (Fig. 6D–F) without affecting body weight (Fig. 6G, 6H), indicating good tolerability. Importantly, treated mice exhibited significantly prolonged survival (Fig. 6I). Discussion Cancer immunotherapy represents an innovative therapeutic strategy that employs immune-based agents to recognize and eliminate tumor cells [28]. Despite its promise, the overall clinical benefit of this approach remains limited, and treatment-related adverse effects continue to be a concern, underscoring the need for more effective combination strategies [29,30]. The tumor microenvironment (TME) plays a critical role in tumorigenesis and metastasis; accordingly, therapeutic approaches targeting the TME have shown encouraging results in clinical trials [31]. Based on this rationale, we established a CT26 colorectal cancer mouse model to systematically evaluate the in vivo antitumor efficacy of the triple combination of APS, HMGN1, and anti-TNFR2 antibody, with particular focus on elucidating the multitarget synergistic mechanisms through which these agents activate immune cells, remodel the TME, and enhance effector T-cell function. Previous studies have shown that anti-TNFR2 antibodies primarily exert their biological effects through specific binding to TNFR2 and modulation of downstream signaling, with minimal Fc-mediated nonspecific effects [32,33]. In this study, we found that the combination of APS and anti-TNFR2 antibody significantly inhibited the proliferation of CRC cells. This effect may be associated with APS-mediated downregulation of TNFR2 expression on the surface of colorectal cancer cells, together with blockade of the interaction between TNFR2 and its ligand by the anti-TNFR2 antibody [34]. The two agents may therefore exert an enhanced inhibitory effect by reducing TNFR2 expression and inhibiting its function, thereby attenuating TNFR2-mediated protumor signaling and ultimately inducing cell cycle arrest and apoptosis. It should be noted that the present study has only validated the in vitro antiproliferative phenotype, and the underlying molecular mechanisms have not yet been directly confirmed. Further studies are therefore warranted to clarify the specific pathways involved and to exclude the possibility that APS exerts its antitumor effects through TNFR2-independent mechanisms. The present study demonstrates for the first time that combined treatment with APS and HMGN1 significantly promotes DC maturation. Co-treatment with these two agents markedly upregulated the expression of the co-stimulatory molecules CD80 and CD86 on the DC surface and enhanced the antigen-presenting capacity of DC. HMGN1, a Th1-polarizing alarmin and canonical TLR4 ligand, directly induces DC maturation through activation of the NF-κB and MAPK signaling pathways, leading to upregulation of co-stimulatory molecules and pro-inflammatory cytokines, including IL-12 and type I interferons, thereby promoting DC maturation and polarization toward a Th1 immune phenotype [23,35]. As a polysaccharide-based immunomodulator, APS appears to serve as an important enhancer of HMGN1-mediated DC maturation by modulating DC activation via the TLR4/MyD88/NF-κB signaling axis, upregulating the expression of MHC-II, CD80, and CD86 on DC surface, promoting DC maturation and the secretion of pro-inflammatory cytokines such as IL-12 and TNF-α, and ultimately enhancing the antigen-presenting function of DC [36]. Notably, this combination strategy may not only circumvent the limitation that prolonged exposure to a single TLR4 agonist tends to induce DC immune tolerance, but also compensate for the inability of APS alone to efficiently initiate the DC antigen-presentation program, thereby providing a critical innate immune basis for robust activation of downstream effector T cells. To further validate the in vivo therapeutic efficacy of the triple therapy, we systematically assessed its antitumor activity and immunomodulatory effects in a CT26 murine model of colorectal cancer (CRC). The results demonstrated that triple therapy significantly suppressed tumor growth, prolonged the overall survival of tumor-bearing mice, and did not induce evident liver or kidney dysfunction or pathological damage in major organs, indicating favorable biocompatibility. Immunophenotypic analysis further revealed a significant increase in intratumoral CD8⁺ cytotoxic T-cell infiltration, accompanied by marked reductions in Tregs and Tim-3⁺ exhausted CD8⁺ T cells, suggesting that the tumor microenvironment was reprogrammed from an immunosuppressive state toward an immune-activated state. Mechanistically, the immunomodulatory effects of this regimen appear to be mediated through coordinated and multilayered interactions among its components. First, the anti-TNFR2 antibody likely serves as a key mediator of Treg blockade by targeting TNFR2, which is highly expressed on the surface of Tregs, thereby inhibiting downstream signaling, suppressing intratumoral Treg expansion and immunosuppressive activity, and disrupting the Treg-derived TGF-β axis that promotes Tim-3 upregulation on CD8⁺ T cells [37]. Second, APS monotherapy significantly reduced the proportion of Tregs in both tumor tissues and tumor-draining lymph nodes, downregulated TGF-β and IL-6 expression, attenuated Treg proliferation and migration, and alleviated effector T-cell exhaustion. Because DCs are key targets of Treg-mediated suppression of antitumor immunity [38], the DC-promoting effects of HMGN1 are particularly relevant in this context. Notably, HMGN1 alone, as well as in combination with APS, promoted DC maturation, enhanced antigen cross-presentation, expanded the pool of tumor-specific effector T cells, and drove CD8⁺ T-cell differentiation toward an effector phenotype, thereby weakening the immunosuppressive niche maintained by Tregs. Consistent with these observations, cytokine profiling showed significantly increased intratumoral levels of IL-2 and TNF-α [39,40], whereas the levels of IL-10, TGF-β, and IL-6 were markedly decreased [[41], [42], [43]]. Together, these findings suggest that the concurrent enhancement of antitumor immunity and attenuation of immunosuppressive signaling likely underlie the robust tumor-inhibitory effects of this triple combination strategy. The combination regimen induced sustained immune memory, as evidenced by the ability of treated mice to reject tumor rechallenge: none of the cured mice developed recurrent tumors, indicating that the treatment not only eradicated the primary tumor, but also established long-term protective immunity. This durable protective effect may be attributed to three synergistic mechanisms: the generation of memory CD8⁺ T lymphocytes, the attenuation of T cell exhaustion via downregulation of Tim-3, and enhanced DC priming during the initial phase of the immune response. Induction of such long-term immunologic memory is a critical hallmark of effective immunotherapy that confers durable antitumor protection. To test whether this therapy could be applied to other types of tumors, experiments were conducted on an invasive breast adenocarcinoma cell line (4T1). This therapy was able to slow down significantly 4T1 growth but did not achieve complete removal of tumors, possibly due to inherent differences between tumor biology and microenvironmental context, particularly by therapeutic resistance mechanisms mediated by stromal components [44]. In general, colorectal cancer models (and in particular MSI-H models), tend to have high mutational load and are rich in neoepitopes, which renders them prone for attack of the adaptive immune system via CD8+ T cells [45,46]. In contrast, breast cancer is frequently associated with impaired antigen-processing capacity, a more immunosuppressive tumor microenvironment, and sustained intrinsic malignant phenotypes, which may collectively constrain therapeutic efficacy [[47], [48], [49], [50], [51], [52]]. This suggests that individualization is essential for any form of immunotherapy, depending on tumor type and its microenvironmental circumstances. Despite the promising preclinical results, several practical challenges remain for clinical translation. The short in vivo half-life of HMGN1 may be overcome through formulation optimization strategies, such as hydrogel-based sustained-release systems or nanoparticle encapsulation [53]. In addition, the intratumoral administration route used in this study is currently limited to tumors amenable to direct injection. Future studies may expand its applicability to deep-seated tumors by developing targeted intravenous delivery systems or integrating image-guided interventional delivery techniques. As a potent immunostimulatory regimen, this combination therapy may also carry a theoretical risk of cytokine release syndrome. During clinical translation, strategies such as step-up dosing and the judicious prophylactic use of low-dose glucocorticoids may help mitigate inflammatory toxicity while preserving antitumor efficacy. The combination of APS, HMGN1, and an anti-TNFR2 antibody proposed in this study may offer distinct translational advantages over existing tumor immunotherapy regimens. First, the translational foundation of its individual components is well established. APS injection has been approved in China as an adjunctive treatment in oncology and has been shown to enhance antitumor efficacy while reducing treatment-related toxicity when combined with radiotherapy or chemotherapy [54]. Meanwhile, anti-TNFR2 antibodies have entered clinical trials for solid tumors, with preliminary findings indicating favorable tolerability and promising antitumor activity [55], thereby potentially reducing the translational risk of this combination strategy. Second, this regimen simultaneously targets major therapeutic barriers in immunologically “cold” tumors, including insufficient dendritic cell-mediated antigen presentation and Treg-driven immunosuppression, making it potentially more tailored than conventional immunotherapeutic approaches. Similar integrative strategies combining traditional Chinese medicine with immunotherapy have also been reported to improve therapeutic responses in cold tumors [56]. Finally, this regimen may hold promise as a neoadjuvant approach for patients with early- to mid-stage resectable CRC by remodeling the tumor microenvironment before surgery and thereby reducing the risk of postoperative recurrence. This remains a major focus of current research on integrated strategies combining traditional Chinese medicine and immunotherapy [57]. Nevertheless, several translational limitations should be acknowledged. APS is still classified as a dietary supplement in Europe and the United States and has not yet been approved as a therapeutic agent. Therefore, future international multicenter clinical studies would require further standardization of product quality control, as well as more comprehensive pharmacokinetic evaluation. In addition, key parameters of the triple-combination regimen, including dose escalation and administration sequence, require further optimization to inform the design of future clinical trials. Although these results are encouraging, several limitations should be acknowledged. First, this study was conducted exclusively in mice. Moreover, the optimal dose and dosing schedule remain to be determined to achieve maximal therapeutic benefit. Although preliminary studies yielded positive results in two tumor models, further work is required to validate these findings across additional cancer subtypes and in human-relevant disease models. Future studies may also explore the potential of this therapeutic strategy in combination with other established immuno-oncology approaches, including anti-PD-1/PD-L1 or anti-CTLA-4 monoclonal antibodies. These issues will need to be addressed to facilitate the clinical translation of this treatment strategy. Conclusion In conclusion, our study demonstrates that the combination of APS, HMGN1, and anti-TNFR2 antibody exerts significant antitumor activity in a colorectal cancer model by remodeling the tumor immune microenvironment and enhancing antitumor immune responses, while also inducing durable immunological memory. Further studies are warranted to elucidate the underlying mechanisms and to evaluate its translational potential across different tumor models. Funding This study was supported by the Shenzhen-Hong Kong Cooperation Zone for Technology and Innovation, the Hong Kong University–Shenzhen Hospital Translational Medicine Centre (HZQSWS-KCCYB-2024055); the San ming Project of Medicine in Shenzhen (SZZYSM202411001); and National Natural Science Foundation of China (82060308) and the Social Security of the People's Republic of China. Data availability Data are available upon reasonable request. Ethics approval and consent to participate The animal study was approved by the Experimental Animal Care and Use Committee (IACUC) of Shenzhen Huarui Model Biotechnology Co., Ltd (IACUC No.: APS-250103-026-01). The study was conducted in accordance with the local legislation and institutional requirements. Consent for publication All authors agreed to submit the manuscript. CRediT authorship contribution statement Liming Zhao: Writing – review & editing, Writing – original draft, Software, Methodology, Investigation, Data curation. Xia Pei: Writing – review & editing, Writing – original draft, Data curation. Haobo Wu: Formal analysis. Shengwen Zhou: Methodology. Jia Song: Formal analysis. Quan Wan: Investigation. Hang Lv: Formal analysis. Jing Xu: Writing – review & editing, Investigation, Funding acquisition. Yingjie Nie: Writing – review & editing, Funding acquisition. Declaration of competing interest The authors declare no competing financial interests or personal relationships that could have influenced the work reported in this paper. Contributor Information Liming Zhao, Email: 15224819659@163.com. Jing Xu, Email: 467343372@qq.com. Yingjie Nie, Email: nieyj@hku-szh.org. References Associated Data Data Availability Statement Data are available upon reasonable request.